{"id":390290,"date":"2019-12-31T00:00:00","date_gmt":"2019-12-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0010-2019-biopharma-biosimilars-emerging-biosimilars-global-2019\/"},"modified":"2026-04-18T23:23:48","modified_gmt":"2026-04-18T23:23:48","slug":"biosbi0010-2019-biopharma-biosimilars-emerging-biosimilars-global-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0010-2019-biopharma-biosimilars-emerging-biosimilars-global-2019\/","title":{"rendered":"Biosimilars | Emerging Biosimilars | Global | 2019"},"content":{"rendered":"<p>The Emerging Biosimilars\u00a0Landscape\u00a0offers extensive coverage of the global <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609521695725963149\">biosimilars<\/gwmw> development landscape. We track over 400\u00a0currently available and novel <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609527490306764077\">biosimilar<\/gwmw> products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609541471351730872\">biosimilar<\/gwmw> launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars\u00a0Landscape\u00a0is updated quarterly.<\/p>\n<p><strong>Questions Answered in This Report:<\/strong><\/p>\n<ul>\n<li><b>How many <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609555178828969742\">biosimilar<\/gwmw> candidates are currently undergoing phase I or III clinical development in a particular region?<\/b><\/li>\n<li><b>Which biologic\u00a0classes and reference molecules are most frequently targeted by <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609562978168200953\">biosimilars<\/gwmw> developers?<\/b><\/li>\n<li><b>Which are the top 10 <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609571128304654178\">biosimilars<\/gwmw> developers by <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854609571120636426084\">number<\/gwmw> of clinical stage candidates?<\/b><\/li>\n<li><b>When is the expected launch date for late stage pipeline candidates in the seven major markets?<\/b><\/li>\n<li><b>What is the level of competition expected for a brand, globally and by region\/country?<\/b><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<ul>\n<li><b>Markets covered:<\/b>\u00a0Global<\/li>\n<li><b>Secondary research:<\/b>\u00a0clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.<\/li>\n<\/ul>\n<p><strong>Mentioned in This Report:<\/strong><\/p>\n<p><em>Key Companies Mentioned<\/em><\/p>\n<ul>\n<li>Amgen<\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609606656666851070\">Biocad<\/gwmw><\/li>\n<li>Biocon<\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609613401930176185\">Celltrion<\/gwmw><\/li>\n<li>Daiichi Sankyo<\/li>\n<li>Dr. Reddy&#8217;s<\/li>\n<li>Fresenius Kabi<\/li>\n<li>Gedeon Richter<\/li>\n<li>Intas<\/li>\n<li>Merck &#038; Co<\/li>\n<li>Mylan<\/li>\n<li>Pfizer<\/li>\n<li>Samsung Bioepis<\/li>\n<li>Sandoz<\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609652439186393637\">Stada<\/gwmw><\/li>\n<\/ul>\n<p><em>Key Drugs Mentioned<\/em><\/p>\n<ul>\n<li>Aranesp<\/li>\n<li>Avastin<\/li>\n<li>Enbrel<\/li>\n<li>Erbitux<\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609670640685542292\">Forteo<\/gwmw><\/li>\n<li>Herceptin<\/li>\n<li>Humira<\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609679887517867126\">Lantus<\/gwmw><\/li>\n<li>Neulasta<\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609685779184838629\">Neupogen<\/gwmw><\/li>\n<li><gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854609688965739338776\">Remicade<\/gwmw><\/li>\n<li>Rituxan \/ MabThera<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390290","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390290\/revisions"}],"predecessor-version":[{"id":576549,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390290\/revisions\/576549"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}